- Company
- 3 generics for Champix have been withdrawn in just one year
- by Lee, Tak-Sun Jul 28, 2021 05:54am
- Varenicline, a smoking cessation drug, is being withdrawn. It is believed that the impurity incident, which occurred last month, affected the cancer. According to the MFDS on the 26th, eight items of Varenicline have been withdrawn since June. On the 22nd of last month, the MFDS also began a safety survey after recovering Pfizer's Champ
- Company
- 19% of valsartan Rxs disappear 3 years after impurity issue
- by An, Kyung-Jin Jul 27, 2021 05:35am
- Three years have passed since the valsartan impurity issue swept across the pharmaceutical industry, however, the valsartan market is still showing no signs of recovery. Prescriptions of products containing valsartan as monotherapy and combination therapy both decreased by nearly 20%. Analysts believe that distrust in valsartan after the imp
- Company
- Sales in the SGLT-2 diabetes drug market rose by 10%
- by Kim, Jin-Gu Jul 27, 2021 05:35am
- Prescription performance of compound drugs has increased significantly in the market for diabetic drugs in the SGLT-2 inhibitors. Outpatient Rx increased by 23% in the second quarter of the year. The single formulation only increased by 4% during the same period, showing slowing down. According to UBIST, a pharmaceutical market research
- Company
- Ultomiris can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 26, 2021 05:51am
- According to related industries, Ultomiris (Ravulizumab), a treatment drug for paroxysmal nocturnal hemoglobinuria (PNH) supplied by Alexion to the domestic market, recently passed the D.C. of Seoul National University Hospital. It will be quickly prescribed after obtaining approval from the MFDS in May last year and being listed on the in
- Company
- Mother's and Kyung Dong won the patent dispute
- by Kim, Jin-Gu Jul 26, 2021 05:50am
- Mother's and Kyungdong Pharmaceutical won the patent dispute over DPP-4 Inhibitor Series Diabetes Complex Tenelia M SR (Metformin HCl + Teneligliptin Hydrobromide Hydrate). This is expected to compete with Genuonescience, which won ahead of the two companies with the early release of generic for Tenelia M SR. According to the pharmace
- Company
- Glaucoma tx Taflotan demonstrates long-term effectiveness
- by Jul 26, 2021 05:49am
- Santen (CEO Lee Han-woong) announced on the 21st that an open-angle glaucoma high-pressure treatment called Taflotan has confirmed the effects of long-term intraocular pressure lowering and glaucoma inhibition in comparison with PGA. The results of the PGA analysis were published in the Journal of Clinical Medicine. The LOTUS study is the
- Company
- Generics for Betmiga, ↑19% market share in just one year
- by Kim, Jin-Gu Jul 23, 2021 05:57am
- Generics for Betmiga (Mirabegron) are gaining market influence. Two generics for market share expanded to 19% in just one year after its launch. The release of generics resulted in a 14% drop in the amount of outpatient prescriptions for the original over a year. According to UBIST, a pharmaceutical market research institute on the 2
- Company
- Sales of Lyrica's generics sales beat Lyrica in nine years
- by Kim, Jin-Gu Jul 23, 2021 05:57am
- For the first time, sales of Lyrica's generics, which is worth &8361;120 billion a year, surpassed the original sales. It is the first time in nine years that a generic has been released in Korea. The reason why it took a relatively long time to expand generic prescription performance is because the original company, Viatris, has regis
- Company
- Optimal doses of Effient and Brilinta different for Koreans
- by Eo, Yun-Ho Jul 22, 2021 05:53am
- The theory that East Asians, including Koreans, require dose adjustments when receiving dual antiplatelet therapy (DAPT) prescriptions is gaining strength. In other words, the ‘East Asian Paradox’ theory that antithrombotics' clinical effect and safety are different for East Asians compared to Westerners is now being recognized worldwide.
- Company
- Celltrion's Regkirona was approved for EUA in Indonesia
- by Kim, Jin-Gu Jul 22, 2021 05:52am
- Celltrion said on the 20th that the coronavirus 19 antibody treatment drug Regkirona (Regdanvimab) has obtained an emergency approval (EUA) from the BPOM. The Indonesian government has approved the emergency use of Regkirona for minor and secondary patients in the high-risk adult group with COVID-19. According to the COVID-19 real-time
